Indications for Spironolactone Use
Spironolactone is FDA-approved for heart failure with reduced ejection fraction (NYHA Class III-IV), hypertension (as add-on therapy), edema from hepatic cirrhosis or nephrotic syndrome, and primary hyperaldosteronism. 1 Beyond these approved indications, spironolactone has substantial evidence supporting its off-label use in acne vulgaris in women and emerging evidence for central serous chorioretinopathy.
FDA-Approved Indications
Heart Failure with Reduced Ejection Fraction
Spironolactone is indicated for NYHA Class III-IV heart failure with reduced ejection fraction to increase survival, manage edema, and reduce hospitalization 1. The 2022 AHA/ACC/HFSA guidelines support its use as part of guideline-directed medical therapy (GDMT) for HFrEF, with emerging evidence for heart failure with mildly reduced ejection fraction (HFmrEF, LVEF 41-49%) 2. Post-hoc analysis of TOPCAT showed benefit in patients with LVEF 44-49%, particularly for reducing cardiovascular mortality 2.
Key consideration: Spironolactone is preferred in HFmrEF patients with poorly controlled hypertension given its dual benefit for blood pressure management 2.
Hypertension
Spironolactone is approved as add-on therapy for hypertension not adequately controlled on other agents 1. This indication is particularly important for resistant hypertension. In a study of 1,411 patients receiving spironolactone as fourth-line therapy, blood pressure fell by 21.9/9.5 mm Hg, with only 6% discontinuing due to adverse effects 3. Another study of 25 patients with refractory hypertension showed 23 of 25 achieved BP <140/90 mm Hg after one month 4.
Edema Management
Spironolactone is indicated for edema in:
- Cirrhosis of the liver when edema is unresponsive to fluid and sodium restriction 1
- Nephrotic syndrome when other measures produce inadequate response 1
For cirrhotic ascites, spironolactone is the drug of choice for initial treatment 5. Start with 100 mg daily, increasing progressively up to 400 mg to achieve adequate natriuresis 5. The 2018 Korean guidelines recommend spironolactone as the mainstay of diuretic treatment for ascites, with loop diuretics added only if spironolactone alone is insufficient 6.
Critical pitfall: In patients with hepatic cirrhosis and ascites, initiate spironolactone in the hospital due to risk of sudden fluid/electrolyte imbalance precipitating hepatic encephalopathy 1. Start with the lowest dose and titrate slowly in cirrhotic patients 1.
Primary Hyperaldosteronism
Spironolactone is indicated for:
- Short-term preoperative treatment
- Long-term maintenance in patients with aldosterone-producing adenomas who are not surgical candidates 1
Off-Label Indications with Strong Evidence
Acne Vulgaris in Women
Spironolactone is an effective systemic alternative to oral antibiotics for acne in women of all ages, not just adult women or those with lower facial distribution 7. The 2016 AAD guidelines support its use based on available evidence, experience, and expert opinion, despite a Cochrane review finding insufficient randomized trial data 8.
Dosing strategy: Start with 100 mg daily in the evening 7. This dose is superior to lower doses and most patients tolerate it well 9. Doses up to 200 mg/day can be used, though side effects increase 7. Several months of treatment is required for full effectiveness 7.
Evidence of effectiveness: Large observational studies show:
- 84% improvement with 100 mg/day, 40% complete clearing 7
- 86% reported improvement with only 4% experiencing side effects 7
- Similar effectiveness to oral antibiotics (14.4% vs 13.4% switching rate within first year) 7
Monitoring: Routine potassium monitoring is not required in young healthy women without hypertension, renal, or cardiac disease, and not taking interacting medications 7, 8. Studies show no increased hyperkalemia rates compared to controls in this population 7.
Pregnancy considerations: Spironolactone is pregnancy category C with potential for feminization of male fetuses 7, 1. Patients should avoid pregnancy while on treatment. Concomitant use of combined oral contraceptives is often recommended to regulate menses and prevent pregnancy 8.
Central Serous Chorioretinopathy (CSC)
Spironolactone shows beneficial effects for non-resolving, persistent, and chronic CSC, including improved visual acuity, reduced choroidal thickness, and reduced subretinal fluid 10.
Dosing for CSC: Studies used 25-50 mg daily, typically starting at 25 mg for one week then increasing to 50 mg daily 10. Treatment duration ranged from 3-12 months 10.
Evidence: In a randomized controlled trial of 30 eyes with acute CSC, 56% achieved complete subretinal fluid resolution at two months with spironolactone versus 8% in controls 10. For steroid-induced CSC, 82% achieved complete resolution even while remaining on glucocorticoids 10.
Important caveat: Patients must be monitored closely for hyperkalemia, which can induce cardiac arrest 10. Those with diabetes, liver disorders, kidney disorders, and elderly patients are at particular risk 10.
Contraindications Across All Indications
Absolute contraindications:
- Significant renal impairment
- Hyperkalemia or medications increasing serum potassium (trimethoprim, ACE inhibitors, ARBs)
- Addison disease
- Acute renal failure
- Anuria
- Concomitant eplerenone or triamterene use 7, 8
Relative contraindications:
- Pregnancy (avoid due to anti-androgenic effects) 1
- Concomitant potassium supplements
- Potent CYP3A4 inhibitors
- Combined ACE inhibitor with ARB 10
Monitoring Requirements
For young healthy women (acne indication): No routine monitoring required 7
For other indications or high-risk patients: Monitor serum potassium, sodium, and renal function at baseline, during therapy, and after dose increases 8. High-risk patients include those with renal/cardiovascular disease, elderly patients, and those taking ACE inhibitors, ARBs, NSAIDs, or digoxin 8.
For cirrhotic patients: Monitor changes in body weight, vital signs, serum creatinine, sodium, and potassium periodically 6. Stop diuretics if serum sodium <120 mmol/L or if significant creatinine increase occurs 6, 5.